Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

RECRUITING

NCT06350097

PHASE3

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

Sponsor: AstraZeneca

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate efficacy and safety of osimertinib (tablet) in combination with Dato-DXd (i.v. infusion) compared with osimertinib (tablet) monotherapyas a first-line therapy in participants with locally advanced or metastatic EGFRm (Ex19del and/or L858R) NSCLC. Study details include: 1. The study duration will be event-driven, with an estimated duration of approximately 9 years. 2. Participants may receive study treatment until disease progression, unacceptable toxicity, or other specific discontinuation criteria are met. 3. The visit frequency will be every 3 weeks during the treatment period. Note: Participants on osimertinib treatment(osimertinib only arm or who have discontinued Dato-DXd while are still receiving osimertinib) are required to attend visits to perform assessments every 6 weeks from Cycle 7 until Cycle 17 and then visits every 12 weeks until disease progression or IP discontinuation. Participants who are receiving osimertinib + Dato-DXd are still required to attend visit to perform assessment every 3 weeks (q3w) per SoA.

Official title: A Phase III, Open-label, Randomised Study of Osimertinib With or Without Datopotamab Deruxtecan (Dato-DXd), as First-line Treatment in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation-positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

582

Start Date

2024-04-29

Completion Date

2032-05-25

Last Updated

2025-11-17

Healthy Volunteers

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

Osimertinib

Arm 1: Osimertinib 80 mg QD as oral tablet with Datopotamab Deruxtecan 6mg/kg as i.v. infusion. Arm 2: Osimertinib 80 mg QD as oral tablet .

DRUG

Datopotamab Deruxtecan

Osimertinib 80 mg QD as oral tablet with Datopotamab Deruxtecan 6mg/kg as i.v. infusion.

Inclusion Criteria: Age 1. Participant must be ≥ 18 years. Type of Participant and Disease Characteristics 2. Histologically or cytologically documented nonsquamous NSCLC. NSCLC of mixed histology is allowed if adenocarcinoma is the predominant histology. Mixed small-cell lung cancer and NSCLC histology, and sarcomatoid variant of NSCLC is ineligible. 3. Stage IIIB or IIIC or Stage IV metastatic NSCLC or recurrent NSCLC (based on the American Joint Committee on Cancer Edition 8) not amenable to curative surgery or definitive chemoradiation at the time of randomisation. 4. Participants must not have received prior EGFR TKIs or other systemic therapy for Stage IIIB, IIIC or IV NSCLC. 5. The tumour harbors at least 1 of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del or L858R), either alone or in combination with other genomic alterations, which may include EGFR T790M, assessed by a CLIA-certified (US sites) or an accredited (outside of the US) local laboratory or by central prospective tissue testing. 6. For participants enrolled in randomisation period, mandatory provision of an unstained, archival tumour tissue sample in a quantity sufficient to allow for central confirmation of the EGFR mutation status. 7. WHO performance status of 0 or 1. 8. At least one lesion not previously irradiated that qualifies as a RECIST 1.1 TL at baseline and can be accurately measured at baseline as ≥10 mm in the longest diameter (except lymph nodes, which must have short axis ≥15 mm) with CT or MRI and is suitable for accurate repeated measurements. 9. Adequate bone marrow reserve and organ function within 7 days before the first dose of study intervention. Sex and Contraceptive/Barrier Requirements 10. Contraceptive use by males or females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Other Inclusion Criteria 11. All races, gender and ethnic groups are eligible for this study. Exclusion Criteria: 1. As judged by the investigator, any evidence of diseases (such as severe or uncontrolled systemic diseases, including active bleeding diseases, psychiatric illness/social situations), history of allogenic organ transplant, and/or substance abuse which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardise compliance with the protocol. 2. Refractory nausea and vomiting, chronic gastrointestinal disease, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption, distribution, metabolism, or excretion of osimertinib. 3. History of another primary malignancy. 4. Spinal cord compression and unstable brain metastases, as defined by Protocol. 5. Clinically significant corneal disease. 6. Has active or uncontrolled hepatitis B or C virus infection, as defined by Protocol. 7. Known HIV infection that is not well controlled, as defined by Protocol. 8. Uncontrolled infection requiring i.v. antibiotics, antivirals or antifungals; suspected infections (eg, prodromal symptoms); or inability to rule out infections (participants with localised fungal infections of skin or nails are eligible). 9. Resting ECG with clinically abnormal findings, as defined by Protocol. 10. Uncontrolled or significant cardiac disease, as defined by Protocol. 11. Past medical history of ILD/penumonitis, including radiation pneumonitis (apart from radiation pneumonitis that did not require steroids), or drug-induced ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at screening. 12. Pulmonary embolism within 3 months of the study enrolment or has severe pulmonary function compromise. Prior/Concomitant Therapy 13. Prior exposure to any agent including an ADC containing a chemotherapeutic agent targeting topoisomerase I, TROP2-targeted therapy. Prior/Concurrent Clinical Study Experience 14. Participants with a known history of severe hypersensitivity reactions to either Dato-DXd and osimertinib or any excipients of Dato DXd and osimertinib or drugs with a similar chemical structure or class to DXd and osimertinib.

Locations (164)

Research Site

Fountain Valley, California, United States

Research Site

Los Alamitos, California, United States

Research Site

Los Angeles, California, United States

Research Site

Los Angeles, California, United States

Research Site

Orange, California, United States

Research Site

San Diego, California, United States

Research Site

Santa Monica, California, United States

Research Site

Walnut Creek, California, United States

Research Site

New Haven, Connecticut, United States

Research Site

Washington D.C., District of Columbia, United States

Research Site

Jacksonville, Florida, United States

Research Site

Ocala, Florida, United States

Research Site

Orange City, Florida, United States

Research Site

Honolulu, Hawaii, United States

Research Site

North Chicago, Illinois, United States

Research Site

Fort Wayne, Indiana, United States

Research Site

Bethesda, Maryland, United States

Research Site

Detroit, Michigan, United States

Research Site

Saint Paul, Minnesota, United States

Research Site

Bridgeton, Missouri, United States

Research Site

St Louis, Missouri, United States

Research Site

Las Vegas, Nevada, United States

Research Site

Brooklyn, New York, United States

Research Site

New York, New York, United States

Research Site

Dallas, Texas, United States

Research Site

Houston, Texas, United States

Research Site

Houston, Texas, United States

Research Site

Webster, Texas, United States

Research Site

Woodway, Texas, United States

Research Site

Fairfax, Virginia, United States

Research Site

Fort Belvoir, Virginia, United States

Research Site

Midlothian, Virginia, United States

Research Site

Seattle, Washington, United States

Research Site

Milwaukee, Wisconsin, United States

Research Site

Camperdown, Australia

Research Site

Clayton, Australia

Research Site

Kogarah, Australia

Research Site

South Brisbane, Australia

Research Site

Westmead, Australia

Research Site

Barretos, Brazil

Research Site

Natal, Brazil

Research Site

Porto Alegre, Brazil

Research Site

Salvador, Brazil

Research Site

São Paulo, Brazil

Research Site

Edmonton, Alberta, Canada

Research Site

Montreal, Quebec, Canada

Research Site

Beijing, China

Research Site

Beijing, China

Research Site

Beijing, China

Research Site

Changchun, China

Research Site

Changsha, China

Research Site

Chengdu, China

Research Site

Chengdu, China

Research Site

Chengdu, China

Research Site

Chongqing, China

Research Site

Chongqing, China

Research Site

Guangzhou, China

Research Site

Hangzhou, China

Research Site

Hangzhou, China

Research Site

Hangzhou, China

Research Site

Harbin, China

Research Site

Hefei, China

Research Site

Hefei, China

Research Site

Jinan, China

Research Site

Jinan, China

Research Site

Kunming, China

Research Site

Linhai, China

Research Site

Ningbo, China

Research Site

Shanghai, China

Research Site

Shanghai, China

Research Site

Shenyang, China

Research Site

Wenzhou, China

Research Site

Wuhan, China

Research Site

Wuhan, China

Research Site

Xi'an, China

Research Site

Xuzhou, China

Research Site

Yangzhou, China

Research Site

Zhengzhou, China

Research Site

Zhengzhou, China

Research Site

Angers, France

Research Site

Marseille, France

Research Site

Paris, France

Research Site

Strasbourg, France

Research Site

Berlin, Germany

Research Site

Cologne, Germany

Research Site

Erfurt, Germany

Research Site

Frankfurt, Germany

Research Site

Göttingen, Germany

Research Site

Immenhausen, Germany

Research Site

Kiel, Germany

Research Site

Mainz, Germany

Research Site

München, Germany

Research Site

Hong Kong, Hong Kong

Research Site

Hong Kong, Hong Kong

Research Site

Jordan, Hong Kong

Research Site

Lai Chi Kok, Hong Kong

Research Site

Bangalore, India

Research Site

Delhi, India

Research Site

Hyderabad, India

Research Site

Kolkata, India

Research Site

Mysuru, India

Research Site

Nagpur, India

Research Site

Nashik, India

Research Site

New Delhi, India

Research Site

New Delhi, India

Research Site

Vadodara, India

Research Site

Varanasi, India

Research Site

Milan, Italy

Research Site

Monza, Italy

Research Site

Orbassano, Italy

Research Site

Padova, Italy

Research Site

Parma, Italy

Research Site

Chūōku, Japan

Research Site

Fukuoka, Japan

Research Site

Kashiwa, Japan

Research Site

Kōtoku, Japan

Research Site

Niigata, Japan

Research Site

Osaka, Japan

Research Site

Osakasayama-shi, Japan

Research Site

Sapporo, Japan

Research Site

Sendai, Japan

Research Site

Wakayama, Japan

Research Site

Yokohama, Japan

Research Site

Bystra, Poland

Research Site

Olsztyn, Poland

Research Site

Poznan, Poland

Research Site

Warsaw, Poland

Research Site

Rio Piedras, Puerto Rico

Research Site

San Juan, Puerto Rico

Research Site

Erie, South Korea

Research Site

Goyang-si, South Korea

Research Site

Namdong-gu, South Korea

Research Site

Seoul, South Korea

Research Site

Seoul, South Korea

Research Site

Seoul, South Korea

Research Site

A Coruña, Spain

Research Site

Barcelona, Spain

Research Site

Granada, Spain

Research Site

Madrid, Spain

Research Site

Majadahonda, Spain

Research Site

Valencia, Spain

Research Site

Taichung, Taiwan

Research Site

Tainan, Taiwan

Research Site

Taipei, Taiwan

Research Site

Taipei, Taiwan

Research Site

Taipei, Taiwan

Research Site

Taoyuan District, Taiwan

Research Site

Bangkok, Thailand

Research Site

Bangkok, Thailand

Research Site

Dusit, Thailand

Research Site

Hat Yai, Thailand

Research Site

Udon Thani, Thailand

Research Site

Adapazarı, Turkey (Türkiye)

Research Site

Ankara, Turkey (Türkiye)

Research Site

Goztepe Istanbul, Turkey (Türkiye)

Research Site

Izmir, Turkey (Türkiye)

Research Site

Küçükçekmece, Turkey (Türkiye)

Research Site

Seyhan, Turkey (Türkiye)

Research Site

Hanoi, Vietnam

Research Site

Hà Nội, Vietnam

Research Site

Ho Chi Minh City, Vietnam

Research Site

Ho Chi Minh City, Vietnam

Research Site

Ho Chi Minh City, Vietnam

Research Site

Vinh, Vietnam

Clinical Research Directory

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

Summary

Key Details

Conditions

Interventions

Eligibility Criteria

Locations (164)